24/7 Market News Snapshot 07 August, 2025 – Palisade Bio, Inc. Common Stock (NASDAQ:PALI)

August 7, 2025

DENVER, Colo., 07 August, 2025 (www.247marketnews.com) – (NASDAQ:PALI) are discussed in this article.
Palisade Bio, Inc. has achieved significant momentum in its stock performance, with shares surging by 49.2% during today’s trading session. Opening at $1.215 and reaching a high of $1.492, this notable increase follows a closing price of $1.000 yesterday. The trading volume for Pali­sa­de Bio exceeded 12.46 million shares, reflecting strong investor interest and potential bullish sentiment toward the company’s future prospects.

Amidst this rally, Palisade Bio is also garnering attention for its clinical advancements, particularly regarding PALI-2108—a promising oral therapy aimed at treating moderate-to-severe ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD). Recent results from its Phase 1b open-label study indicate a 100% clinical response rate among participants, with a substantial mean reduction of 62.8% in the modified Mayo score. Various biomarkers also exhibited histological and immunological improvements, reinforcing the drug’s potential as a leading oral treatment option for these complex conditions.

Chief Executive Officer JD Finley expressed enthusiasm about the groundbreaking results, noting that PALI-2108’s targeted delivery and favorable safety profile enhance its positioning in the therapeutic landscape for patients suffering from these illnesses. Supporting this, pharmacokinetic data reveals that the active metabolite of PALI-2108 remains in colon tissue for over 36 hours post-dose, indicating potential for a convenient once-daily dosing regimen.

As the company prepares for an Investigational New Drug (IND) submission for a Phase 2 trial in the first half of 2026, Palisade Bio is committed to pioneering innovative treatment approaches that prioritize patient needs in autoimmune and inflammatory diseases. With strong market performance and promising clinical results, the future appears bright for Palisade Bio and its stakeholders.

Related news for (PALI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.